VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model

Contributed by: PR Newswire

Tags

VelaVigo-Deal

More Like This

VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate

PR Newswire associated0

Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

(Graphic: Business Wire)

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

PR Newswire associated0

EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement